Cancer Biomark. 2018;22(4):701-707. doi: 10.3233/CBM-181210.
Recent studies have shown that Sulfatase 1 (SULF1) plays a crucial role in the genesis, development, and progression of tumors. However, there have been few studies on the role of SULF1 in pancreatic cancer.
The present study examined the differences in SULF1 expression levels between pancreatic cancer and normal tissues, and their correlation with the clinicopathological features and prognosis.
A total of 65 pancreatic cancer samples were enrolled in this study. An immunohistochemical assay were used in this study. The relationship between SULF1 expression and clinicopathological features were tested using χ2 test or Fisher's exact test. The Kaplan-Meier method was used to calculate the cumulative survival rates of the patients.
The study showed that the SULF1 expression level was higher in pancreatic cancer tissues than in normal tissues. Analysis of the clinical and pathological data of patients revealed that high SULF1 expression was associated with later T, N, and TNM stages, higher CA19-9 levels, smaller tumor size, and poorer prognosis.
These findings suggested that SULF1 could be an indicator of the clinicopathological features and prognosis of pancreatic cancer.
最近的研究表明,硫酸酯酶 1(SULF1)在肿瘤的发生、发展和进展中起着至关重要的作用。然而,关于 SULF1 在胰腺癌中的作用的研究较少。
本研究检测了 SULF1 在胰腺癌组织和正常组织中的表达水平差异及其与临床病理特征和预后的相关性。
本研究共纳入 65 例胰腺癌样本。采用免疫组织化学法检测 SULF1 表达水平。采用卡方检验或 Fisher 确切概率法检测 SULF1 表达与临床病理特征的关系。采用 Kaplan-Meier 法计算患者的累积生存率。
研究表明,SULF1 在胰腺癌组织中的表达水平高于正常组织。对患者的临床和病理数据分析表明,SULF1 高表达与较晚的 T、N 和 TNM 分期、较高的 CA19-9 水平、较小的肿瘤大小和较差的预后相关。
这些发现表明 SULF1 可能是胰腺癌临床病理特征和预后的指标。